Prognostic Trends and Current Challenges in Candidemia: A Comparative Analysis of Two Multicenter Cohorts within the Past Decade

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorAGNELLI, Caroline
dc.contributor.authorGUIMARAES, Thais
dc.contributor.authorSUKIENNIK, Teresa
dc.contributor.authorLIMA, Paulo Roberto Passos
dc.contributor.authorSALLES, Mauro Jose
dc.contributor.authorBREDA, Giovanni Luis
dc.contributor.authorQUEIROZ-TELLES, Flavio
dc.contributor.authorMAGRI, Marcello Mihailenko Chaves
dc.contributor.authorMENDES, Ana Verena
dc.contributor.authorCAMARGO, Luis Fernando Aranha
dc.contributor.authorMORALES, Hugo
dc.contributor.authorDIAS, Viviane Maria de Carvalho Hessel
dc.contributor.authorROSSI, Flavia
dc.contributor.authorCOLOMBO, Arnaldo Lopes
dc.date.accessioned2023-06-21T14:20:07Z
dc.date.available2023-06-21T14:20:07Z
dc.date.issued2023
dc.description.abstractCandidemia remains a major public health challenge due to its high mortality rates, especially in developing countries. Monitoring epidemiological trends may provide insights for better clinical outcomes. This study aimed to describe trends in the epidemiology, therapeutic practices, and mortality in candidemia through a retrospective comparative analysis between two surveillance cohorts of all candidemic adults at eleven tertiary hospitals in Brazil, from 2010-2011 (Period I) versus 2017-2018 (Period II). A total of 616 cases were diagnosed, with 247 being from Period II. These patients were more likely to have three or more coexisting comorbidities [72 (29.1%) vs. 60 (16.3%), p < 0.001], had a prior history of in-hospital admissions more often [102 (40.3%) vs. 79 (21.4%), p = 0.001], and presented with candidemia earlier after admission, within 15 days (0-328) vs. 19 (0-188), p = 0.01. Echinocandins were more frequently prescribed [102 (41.3%) vs. 50 (13.6%), p = 0.001], but time to antifungal initiation [2 days (0-14) vs. 2 (0-13), p = 0.369] and CVC removal within 48 h [90/185 (48.6%) vs. 148/319 (46.4%), p = 0.644] remained unchanged. Additionally, many patients went untreated in both periods I and II [87 (23.6%) vs. 43 (17.4%), p = 0.07], respectively. Unfortunately, no improvements in mortality rates at 14 days [123 (33.6%) vs. 93 (37.7%), p = 0.343] or at 30 days [188 (51.4%) vs. 120 (48.6%), p = 0.511] were observed. In conclusion, mortality rates remain exceedingly high despite therapeutic advances, probably associated with an increase in patients' complexity and suboptimal therapeutic interventions. Management strategies should be tailored to suit epidemiological changes, expedite diagnosis to reduce the number of untreated eligible patients and guarantee early antifungal initiation and source control.eng
dc.description.indexPubMed
dc.description.indexWoS
dc.description.indexScopus
dc.description.sponsorshipFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2017/02203-7]
dc.description.sponsorshipCAPES Foundation [PDSE 88881.187981/2018-01]
dc.identifier.citationJOURNAL OF FUNGI, v.9, n.4, article ID 468, 11p, 2023
dc.identifier.doi10.3390/jof9040468
dc.identifier.eissn2309-608X
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/54165
dc.language.isoeng
dc.publisherMDPIeng
dc.relation.ispartofJournal of Fungi
dc.rightsopenAccesseng
dc.rights.holderCopyright MDPIeng
dc.subjectcandidemiaeng
dc.subjectinvasive candidiasiseng
dc.subjectmortalityeng
dc.subjectprognosiseng
dc.subjectantifungal therapyeng
dc.subject.otherescmid-asterisk guidelineeng
dc.subject.othercritically-ill patientseng
dc.subject.otherinvasive candidiasiseng
dc.subject.otherantifungal therapyeng
dc.subject.othermortalityeng
dc.subject.otherepidemiologyeng
dc.subject.othermanagementeng
dc.subject.otherimpacteng
dc.subject.otherpredictorseng
dc.subject.otherdiagnosiseng
dc.subject.wosMicrobiologyeng
dc.subject.wosMycologyeng
dc.titlePrognostic Trends and Current Challenges in Candidemia: A Comparative Analysis of Two Multicenter Cohorts within the Past Decadeeng
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.author.externalAGNELLI, Caroline:Univ Fed Sao Paulo, Dept Med, Div Infect Dis, Escola Paulista Med, BR-04024002 Sao Paulo, Brazil
hcfmusp.author.externalGUIMARAES, Thais:Hosp Serv Publ Estadual Sao Paulo, BR-04039000 Sao Paulo, Brazil
hcfmusp.author.externalSUKIENNIK, Teresa:Santa Casa Misericordia Porto Alegre, BR-90050170 Porto Alegre, RS, Brazil
hcfmusp.author.externalLIMA, Paulo Roberto Passos:Univ Fed Sao Paulo, Dept Med, Div Infect Dis, Escola Paulista Med, BR-04024002 Sao Paulo, Brazil
hcfmusp.author.externalSALLES, Mauro Jose:Santa Casa Misericordia Sao Paulo, BR-01221010 Sao Paulo, Brazil
hcfmusp.author.externalBREDA, Giovanni Luis:Univ Fed Parana, BR-81531990 Curitiba, Brazil
hcfmusp.author.externalQUEIROZ-TELLES, Flavio:Univ Fed Parana, BR-81531990 Curitiba, Brazil
hcfmusp.author.externalMENDES, Ana Verena:Hosp Sao Rafael, BR-41253190 Salvador, Brazil
hcfmusp.author.externalCAMARGO, Luis Fernando Aranha:Hosp Israelita Albert Einstein, BR-05652900 Sao Paulo, Brazil
hcfmusp.author.externalMORALES, Hugo:Hosp Erasto Gaertner, BR-81520060 Sao Paulo, Brazil
hcfmusp.author.externalDIAS, Viviane Maria de Carvalho Hessel:Hosp Nossa Senhora Gracas, BR-80810040 Curitiba, Brazil
hcfmusp.author.externalCOLOMBO, Arnaldo Lopes:Univ Fed Sao Paulo, Dept Med, Div Infect Dis, Escola Paulista Med, BR-04024002 Sao Paulo, Brazil
hcfmusp.citation.scopus1
hcfmusp.contributor.author-fmusphcMARCELLO MIHAILENKO CHAVES MAGRI
hcfmusp.contributor.author-fmusphcFLAVIA ROSSI
hcfmusp.description.articlenumber468
hcfmusp.description.issue4
hcfmusp.description.volume9
hcfmusp.origemWOS
hcfmusp.origem.pubmed37108922
hcfmusp.origem.scopus2-s2.0-85153954535
hcfmusp.origem.wosWOS:000977556000001
hcfmusp.publisher.cityBASELeng
hcfmusp.publisher.countrySWITZERLANDeng
hcfmusp.relation.referenceAgnelli C, 2022, LANCET REG HEALTH-AM, V6, DOI 10.1016/j.lana.2021.100117eng
hcfmusp.relation.referenceAndes DR, 2012, CLIN INFECT DIS, V54, P1110, DOI 10.1093/cid/cis021eng
hcfmusp.relation.referenceBassetti M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127534eng
hcfmusp.relation.referenceBassetti M, 2014, INTENS CARE MED, V40, P839, DOI 10.1007/s00134-014-3310-zeng
hcfmusp.relation.referenceBattistolo J, 2021, MYCOSES, V64, P1512, DOI 10.1111/myc.13376eng
hcfmusp.relation.referenceBraga PR, 2018, BRAZ J INFECT DIS, V22, P273, DOI 10.1016/j.bjid.2018.07.008eng
hcfmusp.relation.referenceBrescini L, 2022, MYCOPATHOLOGIA, V187, P181, DOI 10.1007/s11046-022-00624-xeng
hcfmusp.relation.referenceChakrabarti A, 2015, INTENS CARE MED, V41, P285, DOI 10.1007/s00134-014-3603-2eng
hcfmusp.relation.referenceClancy CJ, 2018, J CLIN MICROBIOL, V56, DOI 10.1128/JCM.01909-17eng
hcfmusp.relation.referenceColombo AL, 2017, LANCET INFECT DIS, V17, pE344, DOI 10.1016/S1473-3099(17)30304-3eng
hcfmusp.relation.referenceColombo AL, 2006, J CLIN MICROBIOL, V44, P2816, DOI 10.1128/JCM.00773-06eng
hcfmusp.relation.referenceColombo AL, 2014, INTENS CARE MED, V40, P1489, DOI 10.1007/s00134-014-3400-yeng
hcfmusp.relation.referenceColombo AL, 2012, BRAZ J INFECT DIS, V16, pS1, DOI 10.1016/j.bjid.2013.02.001eng
hcfmusp.relation.referenceCornely FB, 2020, MYCOSES, V63, P1373, DOI 10.1111/myc.13177eng
hcfmusp.relation.referenceCornely OA, 2012, CLIN MICROBIOL INFEC, V18, P19, DOI 10.1111/1469-0691.12039eng
hcfmusp.relation.referenceCuenca-Estrella M, 2012, CLIN MICROBIOL INFEC, V18, P9, DOI 10.1111/1469-0691.12038eng
hcfmusp.relation.referencede Oliveira CS, 2021, BRAZ J INFECT DIS, V25, DOI 10.1016/j.bjid.2020.11.006eng
hcfmusp.relation.referenceDimopoulos G, 2012, INT J ANTIMICROB AG, V40, P521, DOI 10.1016/j.ijantimicag.2012.07.018eng
hcfmusp.relation.referenceDoi AM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146909eng
hcfmusp.relation.referenceGarey KW, 2006, CLIN INFECT DIS, V43, P25, DOI 10.1086/504810eng
hcfmusp.relation.referenceGarnacho-Montero J, 2013, J ANTIMICROB CHEMOTH, V68, P206, DOI 10.1093/jac/dks347eng
hcfmusp.relation.referenceGuimaraes T, 2012, INT J INFECT DIS, V16, pE442, DOI 10.1016/j.ijid.2012.02.005eng
hcfmusp.relation.referenceKaur H, 2017, J FUNGI, V3, DOI 10.3390/jof3030041eng
hcfmusp.relation.referenceKim SH, 2013, J ANTIMICROB CHEMOTH, V68, P2890, DOI 10.1093/jac/dkt256eng
hcfmusp.relation.referenceKoehler P, 2019, CLIN MICROBIOL INFEC, V25, P1200, DOI 10.1016/j.cmi.2019.04.024eng
hcfmusp.relation.referenceMazi PB, 2022, CLIN INFECT DIS, V75, P1031, DOI 10.1093/cid/ciac004eng
hcfmusp.relation.referenceMunoz P, 2015, MYCOSES, V58, P14, DOI 10.1111/myc.12329eng
hcfmusp.relation.referenceNucci M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059373eng
hcfmusp.relation.referenceNucci M, 2011, CURR FUNGAL INFECT R, V5, P3, DOI 10.1007/s12281-010-0039-1eng
hcfmusp.relation.referencePapadimitriou-Olivgeris M, 2022, OPEN FORUM INFECT DI, V9, DOI 10.1093/ofid/ofac383eng
hcfmusp.relation.referencePappas PG, 2016, CLIN INFECT DIS, V62, pE1, DOI 10.1093/cid/civ933eng
hcfmusp.relation.referenceVaquero-Herrero MP, 2017, MYCOSES, V60, P676, DOI 10.1111/myc.12644eng
hcfmusp.relation.referencePfaller MA, 2007, CLIN MICROBIOL REV, V20, P133, DOI 10.1128/CMR.00029-06eng
hcfmusp.relation.referencePfaller MA, 2016, MED MYCOL, V54, P1, DOI 10.1093/mmy/myv076eng
hcfmusp.relation.referencePuig-Asensio M, 2014, CRIT CARE MED, V42, P1423, DOI 10.1097/CCM.0000000000000221eng
hcfmusp.relation.referenceTedeschi S, 2016, EUR J INTERN MED, V34, P39, DOI 10.1016/j.ejim.2016.08.020eng
hcfmusp.relation.referenceTseng WP, 2018, ANTIMICROB RESIST IN, V7, DOI 10.1186/s13756-018-0388-zeng
hcfmusp.relation.referenceTumbarello M, 2007, J CLIN MICROBIOL, V45, P1843, DOI 10.1128/JCM.00131-07eng
hcfmusp.relation.referenceValerio M, 2015, CLIN MICROBIOL INFEC, V21, DOI 10.1016/j.cmi.2015.01.013eng
hcfmusp.relation.referenceZatta M, 2020, GERONTOLOGY, V66, P532, DOI 10.1159/000510638eng
hcfmusp.scopus.lastupdate2024-04-12
relation.isAuthorOfPublicationd659102b-c47c-42a8-a6cb-9f0de5c3fbba
relation.isAuthorOfPublicationc23ed5c0-298e-4bc7-acfb-bcaa7ed9ea93
relation.isAuthorOfPublication.latestForDiscoveryd659102b-c47c-42a8-a6cb-9f0de5c3fbba
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
art_AGNELLI_Prognostic_Trends_and_Current_Challenges_in_Candidemia_A_2023.PDF
Tamanho:
302.12 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/03
Artigos e Materiais de Revistas Científicas - LIM/47
Artigos e Materiais de Revistas Científicas - LIM/48